Sunho Biologics Inc. has announced its unaudited consolidated interim results for the six months ended June 30, 2025. The company reported a net loss of RMB38.199 million, an increase from the RMB36.077 million loss in the same period in 2024. Other income saw a significant rise to RMB5.035 million from RMB1.782 million in the previous year. However, there was a notable decrease in other gains and losses, net, which fell to a negative RMB963,000 from a positive RMB38.720 million in 2024. Research and development expenses decreased to RMB28.767 million from RMB37.708 million, and administrative expenses were reduced to RMB12.678 million compared to RMB15.270 million in the prior year. Financial costs increased slightly to RMB826,000 from RMB566,000. The company did not incur any listing expenses during this period, a change from the RMB23.055 million recorded in 2024. The group's total cash and cash equivalents increased significantly from RMB79 million as of December 31, 2024, to RMB171 million as of June 30, 2025. No income tax expense was incurred, and no dividends were declared or proposed for this interim period.